Paradigm, Galaxy back biotech merger to pivot to $888M Hyperliquid treasury strategy

Sonnet BioTherapeutics, a publicly listed biotech firm, has announced a definitive merger agreement with Rorschach I LLC, a newly formed entity backed by Atlas Merchant Capital and other crypto-focused investors, including Paradigm Ventures. According to a July 14 statement, the merged company will adopt a new name, Hyperliquid Strategies, Inc. (HSI), and shift its focus […]